Increasing role of targeted immunotherapies in the treatment of AML
EditorCampese, Antonio F.
International Journal of Molecular Sciences ; 23 (2022), 6. - Art.-Nr. 3304. - eISSN 1422-0067
Link to original publicationhttps://dx.doi.org/10.3390/ijms23063304
InstitutionsUKU. Klinik für Innere Medizin III
Document versionpublished version (publisher's PDF)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The standard of care in medically and physically fit patients is intensive induction therapy. The majority of these intensively treated patients achieve a complete remission. However, a high number of these patients will experience relapse. In patients older than 60 years, the results are even worse. Therefore, new therapeutic approaches are desperately needed. One promising approach in high-risk leukemia to prevent relapse is the induction of the immune system simultaneously or after reduction of the initial tumor burden. Different immunotherapeutic approaches such as allogenic stem cell transplantation or donor lymphocyte infusions are already standard therapies, but other options for AML treatment are in the pipeline. Moreover, the therapeutic landscape in AML is rapidly changing, and in the last years, a number of immunogenic targets structures eligible for specific therapy, risk assessment or evaluation of disease course were determined. For example, leukemia-associated antigens (LAA) showed to be critical as biomarkers of disease state and survival, as well as markers of minimal residual disease (MRD). Yet many mechanisms and properties are still insufficiently understood, which also represents a great potential for this form of therapy. Therefore, targeted therapy as immunotherapy could turn into an efficient tool to clear residual disease, improve the outcome of AML patients and reduce the relapse risk. In this review, established but also emerging immunotherapeutic approaches for AML patients will be discussed.
Is supplemented byhttps://www.mdpi.com/article/10.3390/ijms23063304/s1
Subject headings[GND]: Akute myeloische Leukämie | Immuntherapie
[MeSH]: Leukemia, Myeloid, Acute | Immunotherapy | Molecular targeted therapy
[Free subject headings]: acute myeloid leukemia | leukemia-associated antigens | molecular mechanisms | target structures
[DDC subject group]: DDC 610 / Medicine & health
LicenseCC BY 4.0 International
MetadataShow full item record
DOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-47800